Discriminative ability of the preliminary ACR improvement criteria at different thresholds, EULAR response criterion, ACR and DAS remission criteria to distinguish between two treatment groups at two points of follow up
Criterion | Week 16 | Week 28 | |||||
---|---|---|---|---|---|---|---|
Improved4-150 | χ2 | p Value | Improved4-150 | χ2 | p Value | ||
ACR improvement | |||||||
0% Threshold | 88v 63% | 12.9 | 0.0003 | 82v 62% | 7.3 | 0.007 | |
10% Threshold | 78 v44% | 18.0 | <0.0001 | 74 v49% | 9.7 | 0.002 | |
20%Threshold | 72 v32% | 25.7 | <0.0001 | 72 v49% | 8.6 | 0.003 | |
30% Threshold | 64 v24% | 25.7 | <0.0001 | 67 v39% | 12.1 | 0.0005 | |
40% Threshold | 58v 16% | 28.6 | <0.0001 | 55v 30% | 9.8 | 0.002 | |
50%Threshold | 43 v14% | 16.6 | <0.0001 | 49 v27% | 8.1 | 0.004 | |
60% Threshold | 26 v8% | 9.7 | 0.002 | 37 v22% | 4.4 | 0.04 | |
70%Threshold | 16 v6% | 3.6 | 0.06 | 29 v10% | 8.8 | 0.003 | |
EULAR response | 20.2 | <0.0001 | 13.4 | 0.001 | |||
Good + moderate | 86 v56% | 86 v63% | |||||
Good | 37 v15% | 47 v24% | |||||
ACR remission | |||||||
‘Probable’ | 12v 6% | 1.4 | 0.23 | 21v 11% | 2.7 | 0.10 | |
DAS remission | |||||||
(DAS ⩽1.6) | 12 v9% | 0.4 | 0.54 | 17 v10% | 1.6 | 0.20 |
↵4-150 Combined treatment (n=76) vsulfasalazine treatment (n=79) group.